

NHS Calderdale CCG's response to your request can be found below.

On the 15th September 2021, the MHRA released an alert entitled "[Topical corticosteroids: information on the risk of topical steroid withdrawal reactions](#)" which included advice for healthcare professionals on how to reduce the risk of severe adverse effects that can occur on stopping treatment with topical corticosteroids.

I wish to be sent information about the following:

1. Confirmation as to whether or not this alert has been discussed in any committees. If so I would like to know when this was discussed and see the minutes of the meeting.

This was discussed at Calderdale CCG's Medicines Advisory Group (MAG) on 30th September 2021. The relevant section of the minutes can be seen below:

<p>b) Drug Safety Updates</p> <p>The Drug Safety Updates were reviewed <u>for:-</u></p> <p>August 2021 : No action from Primary care</p> <p>September 2021 : of Note :</p> <p>Topical corticosteroids: information on the risk of topical steroid withdrawal reactions. NB will include in newsletter</p> <p><u>Action</u> : NB to include Topical corticosteroids: information on the risk of topical steroid withdrawal reactions in the next newsletter</p>
--

2. If the GPs under your management are aware of this alert.

The CCG is aware of this:

- All practices should have notifications of the monthly Drug Safety Update.
- In addition, a CCG Safety Newsletter with this information included was sent out to all our member practices following the discussion at the Medicines Advisory Group - the newsletter was sent in the first week of November 2021.

3. What your plans are to monitor patients who are exhibiting symptoms of Topical Steroid Withdrawal reactions

This is not the CCG's responsibility – this would be down to the clinicians responsible for any individual patient exhibiting these symptoms and so the CCG cannot comment further.